{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:50:19Z","timestamp":1777503019077,"version":"3.51.4"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation","doi-asserted-by":"crossref","award":["81371818"],"award-info":[{"award-number":["81371818"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Xiamen Science and Technology Projects","award":["3502Z20131001"],"award-info":[{"award-number":["3502Z20131001"]}]},{"name":"Xiamen Science and Technology Projects","award":["3502Z201410045"],"award-info":[{"award-number":["3502Z201410045"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.antiviral.2015.08.004","type":"journal-article","created":{"date-parts":[[2015,8,8]],"date-time":"2015-08-08T12:16:31Z","timestamp":1439036191000},"page":"101-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Molecular insights into the inhibition of HIV-1 infection using a CD4 domain-1-specific monoclonal antibody"],"prefix":"10.1016","volume":"122","author":[{"given":"Wangheng","family":"Hou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jialong","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruixue","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuangquan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Adam Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaowei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ningshao","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2015.08.004_b0005","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.vaccine.2011.11.089","article-title":"An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site","volume":"30","author":"Ahmed","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2015.08.004_b0010","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1128\/JVI.02097-08","article-title":"Characterization of neutralizing epitopes of varicella-zoster virus glycoprotein H","volume":"83","author":"Akahori","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.08.004_b0015","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1477-3155-10-30","article-title":"Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2","volume":"10","author":"Arora","year":"2012","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.antiviral.2015.08.004_b0020","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1074\/jbc.M708325200","article-title":"Conformational rearrangement within the soluble domains of the CD4 receptor is ligand-specific","volume":"283","author":"Juncadella","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2015.08.004_b0025","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00296-15","article-title":"Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas","volume":"6","author":"Barbian","year":"2015","journal-title":"mBio"},{"key":"10.1016\/j.antiviral.2015.08.004_b0030","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cell.2013.09.061","article-title":"Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys","volume":"155","author":"Barouch","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2015.08.004_b0035","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1002\/j.1460-2075.1993.tb06185.x","article-title":"An antibody that binds the immunoglobulin CDR3-like region of the CD4 molecule inhibits provirus transcription in HIV-infected T cells","volume":"12","author":"Benkirane","year":"1993","journal-title":"EMBO J."},{"key":"10.1016\/j.antiviral.2015.08.004_b0040","doi-asserted-by":"crossref","first-page":"6860","DOI":"10.1128\/IAI.70.12.6860-6870.2002","article-title":"A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts","volume":"70","author":"Birkett","year":"2002","journal-title":"Infect. Immun."},{"key":"10.1016\/j.antiviral.2015.08.004_b0045","doi-asserted-by":"crossref","first-page":"15376","DOI":"10.1073\/pnas.93.26.15376","article-title":"L-selectin activates the Ras pathway via the tyrosine kinase p56lck","volume":"93","author":"Brenner","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2015.08.004_b0050","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1128\/JVI.69.7.4267-4273.1995","article-title":"Synergistic inhibition of human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion and infection by an antibody to CD4 domain 2 in combination with anti-gp120 antibodies","volume":"69","author":"Burkly","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.08.004_b0055","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.4049\/jimmunol.149.5.1779","article-title":"Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion","volume":"149","author":"Burkly","year":"1992","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2015.08.004_b0060","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1128\/JVI.03235-13","article-title":"Nucleic acid chaperone activity associated with the arginine-rich domain of human hepatitis B virus core protein","volume":"88","author":"Chu","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.08.004_b0065","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/bmb\/58.1.43","article-title":"HIV-1 receptors and cell tropism","volume":"58","author":"Clapham","year":"2001","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.antiviral.2015.08.004_b0070","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1099\/0022-1317-83-8-1809","article-title":"Cell surface receptors, virus entry and tropism of primate lentiviruses","volume":"83","author":"Clapham","year":"2002","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2015.08.004_b0075","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3389\/fimmu.2013.00385","article-title":"Human immunodeficiency virus and heparan sulfate: from attachment to entry inhibition","volume":"4","author":"Connell","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.antiviral.2015.08.004_b0080","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/312763a0","article-title":"The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus","volume":"312","author":"Dalgleish","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2015.08.004_b0085","doi-asserted-by":"crossref","first-page":"e1000445","DOI":"10.1371\/journal.ppat.1000445","article-title":"Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site","volume":"5","author":"Dey","year":"2009","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2015.08.004_b0090","first-page":"653","article-title":"Ibalizumab, a CD4-specific mAb to inhibit HIV-1 infection","volume":"8","author":"Dimitrov","year":"2007","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.antiviral.2015.08.004_b0095","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.1074\/jbc.M111.317776","article-title":"Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site","volume":"287","author":"Feng","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2015.08.004_b0100","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0022-1759(97)00195-6","article-title":"Construction and characterization of a radio-iodinatable mutant of recombinant human CD4","volume":"210","author":"Ferrer","year":"1997","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.antiviral.2015.08.004_b0105","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.str.2010.09.017","article-title":"Crystal structure of HIV-1 primary receptor CD4 in complex with a potent antiviral antibody","volume":"18","author":"Freeman","year":"2010","journal-title":"Structure"},{"key":"10.1016\/j.antiviral.2015.08.004_b0110","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1128\/JVI.72.4.3340-3350.1998","article-title":"Human immunodeficiency virus neurotropism: an analysis of viral replication and cytopathicity for divergent strains in monocytes and microglia","volume":"72","author":"Ghorpade","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.08.004_b0115","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1529\/biophysj.104.044933","article-title":"Entropy calculation of HIV-1 Env gp120, its receptor CD4, and their complex: an analysis of configurational entropy changes upon complexation","volume":"88","author":"Hsu","year":"2005","journal-title":"Biophys. J."},{"key":"10.1016\/j.antiviral.2015.08.004_b0120","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1128\/AAC.00942-08","article-title":"Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults","volume":"53","author":"Jacobson","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.08.004_b0125","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1086\/380802","article-title":"Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1","volume":"189","author":"Kuritzkes","year":"2004","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2015.08.004_b0130","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.immuni.2012.08.012","article-title":"Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies","volume":"37","author":"Kwong","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.antiviral.2015.08.004_b0135","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nature12053","article-title":"Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus","volume":"496","author":"Liao","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2015.08.004_b0140","doi-asserted-by":"crossref","first-page":"7588","DOI":"10.1128\/JVI.00734-12","article-title":"The development of CD4 binding site antibodies during HIV-1 infection","volume":"86","author":"Lynch","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.08.004_b0145","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0092-8674(86)90590-8","article-title":"The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain","volume":"47","author":"Maddon","year":"1986","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2015.08.004_b0150","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1089\/088922201753342059","article-title":"Postattachment neutralization of a primary strain of HIV type 1 in peripheral blood mononuclear cells is mediated by CD4-specific antibodies but not by a glycoprotein 120-specific antibody that gives potent standard neutralization","volume":"17","author":"McInerney","year":"2001","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.antiviral.2015.08.004_b0155","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1128\/JVI.66.8.4784-4793.1992","article-title":"A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells","volume":"66","author":"Moore","year":"1992","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.08.004_b0160","doi-asserted-by":"crossref","first-page":"024905","DOI":"10.1063\/1.4812801","article-title":"Simulations reveal that the HIV-1 gp120-CD4 complex dissociates via complex pathways and is a potential target of the polyamidoamine (PAMAM) dendrimer","volume":"139","author":"Nandy","year":"2013","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.antiviral.2015.08.004_b0165","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.3390\/v4091731","article-title":"Neutralization interfering antibodies: a \u201cnovel\u201d example of humoral immune dysfunction facilitating viral escape?","volume":"4","author":"Nicasio","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2015.08.004_b0170","doi-asserted-by":"crossref","first-page":"13540","DOI":"10.1073\/pnas.1304985110","article-title":"Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1","volume":"110","author":"Pace","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2015.08.004_b0175","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/nsmb.2600","article-title":"Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16","volume":"20","author":"Pancera","year":"2013","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.antiviral.2015.08.004_b0180","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1586\/erv.10.77","article-title":"Back to the future: covalent epitope-based HIV vaccine development","volume":"9","author":"Paul","year":"2010","journal-title":"Exp. Rev. Vaccines"},{"key":"10.1016\/j.antiviral.2015.08.004_b0185","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1128\/JVI.72.4.2855-2864.1998","article-title":"Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1","volume":"72","author":"Platt","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.08.004_b0190","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1128\/JVI.77.1.713-718.2003","article-title":"CD4 binding site antibodies inhibit human immunodeficiency virus gp120 envelope glycoprotein interaction with CCR5","volume":"77","author":"Raja","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.08.004_b0195","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1128\/JVI.79.9.5616-5624.2005","article-title":"An unrelated monoclonal antibody neutralizes human immunodeficiency virus type 1 by binding to an artificial epitope engineered in a functionally neutral region of the viral envelope glycoproteins","volume":"79","author":"Ren","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.08.004_b0200","doi-asserted-by":"crossref","first-page":"164203","DOI":"10.1155\/2013\/164203","article-title":"HIV-1 trans infection of CD4(+) T cells by professional antigen presenting cells","volume":"2013","author":"Rinaldo","year":"2013","journal-title":"Scientifica"},{"key":"10.1016\/j.antiviral.2015.08.004_b0205","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/348419a0","article-title":"Crystal structure of an HIV-binding recombinant fragment of human CD4","volume":"348","author":"Ryu","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2015.08.004_b0210","doi-asserted-by":"crossref","first-page":"9187","DOI":"10.1128\/JVI.75.19.9187-9200.2001","article-title":"Syndecans serve as attachment receptors for human immunodeficiency virus type 1 on macrophages","volume":"75","author":"Saphire","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.08.004_b0215","first-page":"a006841","article-title":"Origins of HIV and the AIDS pandemic","volume":"1","author":"Sharp","year":"2011","journal-title":"Cold Spring Harbor Persp. Med."},{"key":"10.1016\/j.antiviral.2015.08.004_b0220","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nature12746","article-title":"Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia","volume":"503","author":"Shingai","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2015.08.004_b0225","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1016\/j.bmc.2013.05.038","article-title":"Molecular docking guided structure based design of symmetrical N,N\u2032-disubstituted urea\/thiourea as HIV-1 gp120-CD4 binding inhibitors","volume":"21","author":"Sivan","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.antiviral.2015.08.004_b0230","doi-asserted-by":"crossref","first-page":"6935","DOI":"10.1128\/JVI.00453-10","article-title":"Epitope mapping of ibalizumab, a humanized anti-CD4 monoclonal antibody with anti-HIV-1 activity in infected patients","volume":"84","author":"Song","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.08.004_b0235","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/nbt.2677","article-title":"Strategic addition of an N-linked glycan to a monoclonal antibody improves its HIV-1-neutralizing activity","volume":"31","author":"Song","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.antiviral.2015.08.004_b0240","doi-asserted-by":"crossref","first-page":"11502","DOI":"10.1128\/JVI.05363-11","article-title":"Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals","volume":"85","author":"Tomaras","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.08.004_b0245","doi-asserted-by":"crossref","first-page":"10799","DOI":"10.1073\/pnas.191124098","article-title":"Crystal structure of the human CD4 N-terminal two-domain fragment complexed to a class II MHC molecule","volume":"98","author":"Wang","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2015.08.004_b0250","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/348411a0","article-title":"Atomic structure of a fragment of human CD4 containing two immunoglobulin-like domains","volume":"348","author":"Wang","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2015.08.004_b0255","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1128\/AAC.46.6.1896-1905.2002","article-title":"Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy","volume":"46","author":"Wei","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.08.004_b0260","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature01470","article-title":"Antibody neutralization and escape by HIV-1","volume":"422","author":"Wei","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2015.08.004_b0265","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.cell.2014.01.052","article-title":"Structural insights on the role of antibodies in HIV-1 vaccine and therapy","volume":"156","author":"West","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2015.08.004_b0270","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/387527a0","article-title":"Dimeric association and segmental variability in the structure of human CD4","volume":"387","author":"Wu","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2015.08.004_b0275","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/infdis\/jit638","article-title":"The impact of hepatitis B virus precore\/core gene carboxyl terminal mutations on viral biosynthesis and the host immune response","volume":"209","author":"Wu","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2015.08.004_b0280","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1166\/jnn.2005.221","article-title":"DNA vaccine against Taenia solium cysticercosis expressed as a modified hepatitis B virus core particle containing three epitopes shared by Taenia crassiceps and Taenia solium","volume":"5","author":"Wu","year":"2005","journal-title":"J. Nanosci. Nanotechnol."},{"key":"10.1016\/j.antiviral.2015.08.004_b0285","doi-asserted-by":"crossref","first-page":"5077","DOI":"10.1128\/JVI.02600-08","article-title":"Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain","volume":"83","author":"Wu","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.08.004_b0290","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/31514","article-title":"The antigenic structure of the HIV gp120 envelope glycoprotein","volume":"393","author":"Wyatt","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2015.08.004_b0295","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/0092-8674(93)90511-N","article-title":"A kinase-independent function of Lck in potentiating antigen-specific T cell activation","volume":"74","author":"Xu","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2015.08.004_b0300","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1128\/AAC.00761-05","article-title":"Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody (TNX-355) and enfuvirtide (T-20)","volume":"50","author":"Zhang","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.08.004_b0305","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1126\/science.1192819","article-title":"Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01","volume":"329","author":"Zhou","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2015.08.004_b0310","doi-asserted-by":"crossref","first-page":"10892","DOI":"10.1128\/JVI.75.22.10892-10905.2001","article-title":"Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41","volume":"75","author":"Zwick","year":"2001","journal-title":"J. Virol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215001904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215001904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T20:16:40Z","timestamp":1691871400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354215001904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":62,"alternative-id":["S0166354215001904"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.08.004","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular insights into the inhibition of HIV-1 infection using a CD4 domain-1-specific monoclonal antibody","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}